Recent Financings of Private Companies (09/11)
This article was originally published in Start Up
Executive Summary
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
You may also be interested in...
Device Week, 22 September 2021 – Who Pays When Robotic Assisted Surgery Goes Awry?
On this week’s podcast: One of the more interesting and important trends in medtech in recent years is the emergence of robotic assisted surgery. But as RAS procedures increase, so do the chances of something going wrong. And when it does, who’s to blame? The robot or the surgeon?
Deals In Depth: August 2021
Two $2bn+ alliances were penned in August. Topping the list was a multi-target deal between Shape Therapeutics and Roche that could exceed $3bn. Through the partnership, ShapeTX will apply its proprietary RNA editing platform RNAfix and potentially leverage its AAVid technology platform for next-generation tissue-specific adeno-associated viruses for the development of gene therapy for certain targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases. Roche is responsible for the development and worldwide commercialization of any potential products resulting from the collaboration. In the top August M&A by deal value, Sanofi entered into a definitive agreement to acquire all outstanding shares of public messenger RNA therapeutics company Translate Bio for $38.00 per share in cash (a 20% premium to Translate's 10-day pre-announcement market average), which represents a total equity value of approximately $3.2bn. Founded in 2011, Translate Bio is developing a new class of medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. The company is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis in a Phase I/II clinical trial. Its MRT platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as oncology. Financing reached $4.4bn in biopharma, $1.5bn in device, and $256m in diagnostics.
EMA’s Emer Cooke On The Future Of Rolling Reviews & The End Of Remote Meetings
Emer Cooke, executive director of the European Medicines Agency, has offered some insights into how the agency’s working may change following the COVID-19 pandemic, including the development of hybrid inspections.